

CITATION REPORT

List of articles citing

Amivantamab: First Approval

DOI: 10.1007/s40265-021-01561-7
Drugs, 2021, 81, 1349-1353.

Source: <https://exaly.com/paper-pdf/81474055/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
44	Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2021 , 1	3.6	1
43	Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Medical Science Monitor</i> , 2021 , 27, e934854	3.2	3
42	Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
41	Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors. <i>Cancers</i> , 2021 , 13,	6.6	1
40	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015		1
39	Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.. <i>Frontiers in Molecular Biosciences</i> , 2022 , 9, 847835	5.6	3
38	Novel targeted therapies for advanced non-small lung cancer.. <i>Seminars in Oncology</i> , 2022 ,	5.5	0
37	Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: A review of phase II and III trials.. <i>Expert Opinion on Emerging Drugs</i> , 2022 ,	3.7	0
36	Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions.. <i>Biomedicines</i> , 2021 , 9,	4.8	5
35	Amivantamab for the treatment of exon 20 insertion mutant non-small cell lung cancer.. <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-14	3.5	1
34	EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives.. <i>Biomarker Research</i> , 2022 , 10, 21	8	0
33	Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.. <i>Biomarker Research</i> , 2022 , 10, 20	8	2
32	Treatment Strategies and Outcomes for Patients with EGFR-mutant Non-Small Cell Lung Cancer Resistant to EGFR Tyrosine Kinase Inhibitors: Focus on Novel Therapies. <i>Lung Cancer</i> , 2022 ,	5.9	2
31	Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5686	6.3	2
30	Perioperative targeted therapy for oncogene-driven NSCLC. <i>Lung Cancer</i> , 2022 ,	5.9	1
29	Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography. <i>Bioresources and Bioprocessing</i> , 2022 , 9,	5.2	0
28	Lazertinib: on the Way to Its Throne. 2022 , 63, 799		0

27	Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review. 13,	0
26	Adverse Renal Effects of Anticancer Immunotherapy: A Review. 2022 , 14, 4086	
25	Effective flow-through polishing strategies for knob-into-hole bispecific antibodies. 2022 , 9,	0
24	Nanoparticle-based immunotherapy of pancreatic cancer. 9,	0
23	Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody. 13,	0
22	Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021. 2022 , 10, 2325	1
21	Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab \square bispecific antibody against solid tumors. 2022 , 227, 152283	0
20	Current status of immunotherapy for non-small cell lung cancer. 13,	1
19	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. 2022 , 15,	1
18	Immunotherapeutic progress and application of bispecific antibody in cancer. 13,	1
17	Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations. Volume 15, 1197-1210	0
16	Development of therapeutic antibodies for the treatment of diseases. 2022 , 3,	1
15	Overcoming Barriers to Preventing and Treating P. aeruginosa Infections Using AAV Vected Immunoprophylaxis. 2022 , 10, 3162	0
14	Emerging Antibodies in Cancer Therapy. 2200083	0
13	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. 2022 , 3,	0
12	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. 2022 , 15,	1
11	Anti-EGFR Therapy in Gallbladder Cancer. 2023 , 331-349	0
10	Current status of anti-EGFR agents. 2023 , 1-12	0

- 9 Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer. **2022**, 24, 613-648 ○
- 8 Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. **2023**, 66, 3135-3172 ○
- 7 Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis. **2023**, 23, 307-318 ○
- 6 CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2 / CD98 antibody inhibits the growth signal of human breast cancer cells. ○
- 5 Current status and future perspectives of bispecific antibodies in the treatment of lung cancer. **2023**, 136, 379-393 ○
- 4 Immunotargeting of Cancer Stem Cells. **2023**, 15, 1608 ○
- 3 Antibody-Drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. **2023**, 46, 131-148 1
- 2 Amivantamab (JNJ-61186372)-induced adverse cutaneous reaction. 1-8 ○
- 1 Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. **2023**, 26, 106540 ○